El pasado día 16 de junio de 2017 tuvo lugar en FISABIO la Tercera Conferencia organizada por la Cátedra FISABIO-UV a cargo del Prof. Salvador Moncada sobre «Inversión en Salud: Tratamiento o Prevención. El Caso de Manchester».
Durante su ponencia, el Prof. Moncada afirmó que «La única forma es prevenir y tratar tempranamente para reducir el peso específico del Cáncer y destinar los recursos a los enfermos».
También afirmó que «En 2030-40, 1 de cada 2 personas sufrirá un cáncer en algún momento de su vida en Reino Unido».
Prof. Salvador Moncada
Professor Moncada's scientific career began at the Royal College of Surgeons, where he was part of the team that discovered the mechanism of action of aspirin-like drugs, thus explaining their therapeutic actions as well as their main side effect, gastric damage. During his time at the Wellcome Research Laboratories he led the team that discovered thromboxane synthase and the vasodilator prostacyclin. This work is the bases for the understanding of how, low doses of aspirin, prevent cardiovascular events such as heart attacks and strokes and it also explains the cardiovascular side effects of the so-called COX2 inhibitors.
In the 1980's he identified nitric oxide as a biological mediator, the mechanism of its biosynthesis and many of its biological functions. As Director of Research at Wellcome, he oversaw the work that resulted in the discovery and development of several new medicines, including, Lamotrigine, Atovaquone, Somig and Lapatinib. In 1995 he founded the Wolfson Institute for Biomedical Research at University College London, which he directed until 2013. Since 2013 he is at the University of Manchester, first as a Director of the Institute of Cancer Sciences and now as Cancer Domain Director.